• Cytokine Growth Factor Rev. · Jun 2020

    Letter Review

    COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.

    • Shivraj Hariram Nile, Arti Nile, Jiayin Qiu, Lin Li, Xu Jia, and Guoyin Kai.
    • Department of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.
    • Cytokine Growth Factor Rev. 2020 Jun 1; 53: 66-70.

    AbstractThe outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into an unprecedented global pandemic. Clinical investigations in patients with COVID-19 has shown a strong upregulation of cytokine and interferon production in SARS-CoV2- induced pneumonia, with an associated cytokine storm syndrome. Thus, the identification of existing approved therapies with proven safety profiles to treat hyperinflammation is a critical unmet need in order to reduce COVI-19 associated mortality. To date, no specific therapeutic drugs or vaccines are available to treat COVID-19 patients. This review evaluates several options that have been proposed to control SARS-CoV2 hyperinflammation and cytokine storm, eincluding antiviral drugs, vaccines, small-molecules, monoclonal antibodies, oligonucleotides, peptides, and interferons (IFNs).Copyright © 2020 Elsevier Ltd. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!

We guarantee your privacy. Your email address will not be shared.